Prolonged release Fampridine improves walking speed and quality of life in people with multiple sclerosis (MS). Licensed by European Medicines Agency (2011) it is not reimbursed on the NHS.Objectives
To assess effect of PR-Fampridine on walking speed, quality of life and functional ability in a novel ‘MS walking clinic’.Methodology
People with MS related walking impairment were reviewed in complex specialist clinic. Treatments included functional electrical stimulation (FES), anti-spasmodics, PR-fampridine, physiotherpy. Outcomes: Timed-25-Foot Walk (T25FW), Multiple Sclerosis Walking Scale (MSWS-12), EuroQol5 (EQ-5D-5L), VAS walking, functional goals. Data was collected at baseline, 2–3 weeks and 4 monthly therafter. Responders were defined by ≥20% increase T25FW in baseline velocity with concomitant MSWS-12 improvement.Results
269 subjects included. Mean age 52.3 [34–73 years], 186 female and 83 male. Mean Expanded Disability Status Score (EDSS) 6.39 [6.0–7.0]. 117 were timed walk (TW) responders (43%) with 65.0% improvement compared with 10.8% in TWnon-responders (p<0.0001). MSWS-12 improved in responders (−18.1, p=0.023) not in non-responders (−10.6, ns). EQ-5D-5L showed greater improvement responders compared with non-responders (0.119 vs 0.026, p=0.032). Response was sustained for up to 3 years.Conclusion
PR-Fampridine improves walking speed, self-reported walking ability and quality of life in an open-label longitudinal study of MS patients.